A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy.

R. E. Hough, P. C. Lorigan, C. Poynton, A. Newland, R. K. Gupta, J. Foran, B. W. Hancock

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The aim of this study was to determine whether administration of BB-10010, a synthetic stem cell inhibitor, would allow more intensive chemotherapy to be administered to patients with newly diagnosed high grade NHL. Thirteen patients were randomised to receive BB-10010 concurrently with dose-intensified BEMOP/CA chemotherapy (7 patients) or chemotherapy alone (6 patients). Although the mean neutrophil count of BB-10010 treated patients was higher following cycles 1, 2 and 3 of chemotherapy compared with those receiving chemotherapy alone, there was no difference in the mean number of cycles tolerated, blood component usage and hospital admissions due to infections. No specific toxicity of BB-10010 was identified. Whilst BB-10010 can be administered safely, it does not improve the ability of patients to tolerate intensive chemotherapy for high grade NHL.

Original languageEnglish (US)
Pages (from-to)421-424
Number of pages4
JournalInternational journal of oncology
Volume22
Issue number2
StatePublished - Feb 2003

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hough, R. E., Lorigan, P. C., Poynton, C., Newland, A., Gupta, R. K., Foran, J., & Hancock, B. W. (2003). A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy. International journal of oncology, 22(2), 421-424.